Author

Jayant Sancheti

Institutions: Novartis (Switzerland), Novartis (India)

Observed institutions: Novartis (Switzerland), Novartis (India)

OpenAlex ID: A5151027090

Pharmacokinetics of ganaplacide and lumefantrine in a pediatric population with Plasmodium falciparum uncomplicated malaria, treated with ganaplacide plus lumefantrine solid dispersion formulation: analysis of data from KALUMI, a multinational Phase 2 study

2026 · Ramachandra Sangana, Bakary Fofana, et al. · Research Square

Ganaplacide plus lumefantrine solid dispersion formulation for children with uncomplicated Plasmodium falciparum malaria (KALUMI): an open-label, multicentre, randomised, controlled, adaptive, phase 2, non-inferiority trial

2026 · Bakary Fofana, Rella Zoleko-Manego, et al. · The Lancet Infectious Diseases

IID432, a parasite-selective topoisomerase II inhibitor, achieves rapid single-dose parasite clearance in a murine chronic Chagas model

2026 · Manuel Saldivia, Rajiv S. Jumani, et al. · Proceedings of the National Academy of Sciences

Works count: 4

Citation count:

H-index:

I10-index: